Recent studies have shown that certain combinations of Toll-like receptor (TLR) agonists can induce synergistic immune activation. However, it remains challenging to achieve such robust responses in vivo in a manner that is effective, facile, and amenable for clinical translation. Here, we show that MPLA, a TLR4 agonist, and CpG, a TLR9 agonist, can be efficiently co-loaded into synthetic high-density lipoprotein nanodiscs, forming a potent adjuvant system (ND-MPLA/CpG) that can be readily combined with a variety of subunit antigens, including proteins and peptides. ND-MPLA/CpG significantly enhanced activation of dendritic cells, compared with free dual adjuvants or nanodiscs delivering a single TLR agonist. Importantly, mice immunized with physical mixtures of protein antigens ND-MPLA/CpG generated strong humoral responses, including induction of IgG responses against protein convertase subtilisin/kexin 9 (PCSK9), leading to 17-30% reduction of the total plasma cholesterol levels. Moreover, ND-MPLA/CpG exerted strong anti-tumor efficacy in multiple murine tumor models. Compared with free adjuvants, ND-MPLA/CpG admixed with ovalbumin markedly improved antigenspecific CD8+ T cell responses by 8-fold and promoted regression of B16F10-OVA melanoma (P < 0.0001). Furthermore, ND-MPLA/CpG admixed with E7 peptide antigen elicited~20% E7-specific CD8+ T cell responses and achieved complete regression of established TC-1 tumors in all treated animals. Taken together, our work highlights the simplicity, versatility, and potency of dual TLR agonist nanodiscs for applications in vaccines and cancer immunotherapy.
Introduction
Vaccination is a powerful medical intervention that is proven to be effective in the settings of infectious diseases, cancer, and many pathologies [1] [2] [3] . Compared with live attenuated or killed vaccines, vaccines based on subunit antigens, such as recombinant proteins or peptide antigens, are more attractive due to their safety and ease of manufacturing and quality control [4] [5] [6] [7] . However, because of their low immunogenicity, subunit antigens need to be administered with immune-stimulating adjuvants to promote immune responses [8] . Among various adjuvant molecules, Toll-like receptor (TLR) agonists have been studied extensively [9, 10] . TLR agonists can activate dendritic cells to upregulate costimulatory ligands and secrete pro-inflammatory cytokines, thereby providing critical signals to the adaptive immune system for induction of cellular and humoral immune responses [11] .
Notably, recent studies have indicated synergy between various combinations of TLR agonists [12, 13] . Specifically, monophosphoryl lipid A (MPLA, a TLR4 agonist) and CpG-rich oligonucleotide (CpG, a TLR9 agonist) activate dendritic cells (DCs) via two distinct pathways. MPLA triggers the interferon regulatory factor 3 (IRF3) pathway via Toll/IL-1R domain-containing adaptor inducing IFN-β (TRIF) and is currently used in the clinic [10, 14, 15] . CpG activates nuclear factor kappa B (NF-ΚB) via myeloid differentiation primary response gene 88 (MyD88) [16] [17] [18] , and a hepatitis B vaccine (HEPLISAV-B™, Dynavax Technologies Corporation, Berkeley, CA) containing CpG oligonucleotide-1018 as an adjuvant was approved by the US Food and Drug Administration (FDA) for clinical use on November 9, 2017 [19] . Importantly, potent synergy between TLR4 and TLR9 agonists in activation of antigen-presenting cells has been documented in vitro [12, 13] , and their in vivo efficacy to generate adaptive immune responses have been recently reported using adjuvant delivery systems [20] [21] [22] [23] . Despite these advances, there is still a need for a general methodology that can achieve potent immune activation with combinations of TLR agonists, especially in a manner that is effective, facile, and amenable for clinical translation.
Here, we propose a simple strategy for co-delivering multiple TLR agonists in vivo that can be readily formulated with a variety of subunit antigens. Previously, synthetic high-density lipoprotein (sHDL), either made from recombinant apolipoproteins or obtained from endogenous plasma has been examined as delivery vehicles for various cargo molecules [24] [25] [26] [27] . In our own prior work, we have reported the development of sHDL nanodiscs (ND), composed of biocompatible phospholipids and apolipoprotein A1 (ApoA1)-mimetic peptide [28] . We have demonstrated their versatility to deliver a wide range of therapeutics, including chemotherapeutics, imaging agents, and nucleic acids [28] [29] [30] [31] [32] . Additionally, we have recently shown that ND loaded with peptide antigens and a TLR9 agonist efficiently drained to local draining lymph nodes and induced strong antigen-specific T cell responses against cancer cells [33] . Here, we show that ND serves as an effective delivery platform for dual TLR agonists and demonstrate their adaptability and potency with a range of subunit antigens, including protein and peptide antigens.
In this current study, we report that sHDL ND allowed for efficient incorporation (> 80% efficiency) of MPLA. Additionally, as sHDL ND is a good acceptor for cholesterol [28] , we have employed cholesterolmodified CpG for loading into sHDL ND and achieved > 95% incorporation efficiency for CpG. The resulting ND co-loaded with the dual adjuvants (ND-MPLA/CpG) was more effective at activation and maturation of DCs, compared with free dual adjuvants or even ND containing either MPLA or CpG. Immunizations with ND-MPLA/CpG physically mixed with protein antigens generated strong humoral immune responses in vivo, including induction of antibody responses against protein convertase subtilisin/kexin 9 (PCSK9), leading to 17-30% reduction of the total plasma cholesterol levels in mice. Importantly, ND-MPLA/CpG also served as a potent adjuvant system for elicitation of cellular immune responses in vivo. Compared with free adjuvants, ND-MPLA/CpG admixed with a model antigen protein, ovalbumin (OVA), significantly improved antigen-specific CD8+ T cell responses in B16F10-OVA tumor-bearing mice, inducing regression of established melanoma tumors. Finally, we have also confirmed these results using the TC-1 tumor cell line expressing the E7 oncogene from human papillomavirus (HPV) type 16. Immunizations with ND-MPLA/ CpG admixed with E7 antigen peptide elicited~20% E7-specific antigen-specific CD8+ T cells and exerted potent anti-tumor efficacy against established TC-1 tumors. Overall, our results demonstrate that ND-MPLA/CpG is a promising adjuvant system for vaccination and immunotherapy.
Materials & methods

Reagents
1,2-Dimyristoyl-sn-glycero-3-phosphocholine (DMPC) was purchased from Nippon Oils and Fats (Osaka, Japan). ApoA1 mimetic peptide 22A (PVLDLFRELLNELLEALKQKLK) was synthesized by GenScript Corp (Piscataway, NJ). MPLA was purchased from Avanti Polar Lipids (Alabaster, AL). 1,1′-Dioctadecyl-3,3,3′,3′-Tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate salt (DiD) was purchased from Invitrogen. CpG1826 modified with cholesterol at the 3′ end (labeled as CpG throughout this manuscript) was synthesized by Integrated DNA Technologies (Coralville, IA). Ovalbumin (OVA) was purchased from Worthington (Lakewood, NJ). Recombinant human protein convertase subtilisin/kexin 9 (hPCSK9) was purchased from BioLegend (San Diego, CA 
Preparation of ND-MPLA/CpG
sHDL nanodiscs (ND) were prepared by using the lyophilization method, as we reported previously [29, 31, 32] . To load MPLA into ND, MPLA was co-dissolved with DMPC and 22A at the weight ratio of 0.01:2:1 in acetic acid, followed by lyophilization and hydration with PBS to form ND-MPLA. To load CpG in ND-MPLA, CpG1826 modified with cholesterol at the 3′ end (i.e. CpG) was incubated with pre-formed ND-MPLA for 30 min at room temperature. In some experiments, 0.3% mol of DiD was mixed with lipids to prepare DiD-labeled nanodiscs.
Characterization of ND-MPLA/CpG
The loading efficiency of MPLA in ND-MPLA was measured by HPLC equipped with an evaporative light scattering detector (ELSD) as described before [34] . The loading efficiency of CpG was measured by gel permeation chromatography (GPC), as we reported previously [33] . Briefly, ND samples were injected in a Shimadzu HPLC system equipped with a TSKgel G2000SWxl column (7.8 mm ID × 30 cm, Tosoh Bioscience LLC), and the amount of CpG was quantified with the detection wavelength set at 280 nm. The particle size of ND-MPLA/CpG was measured by dynamic light scattering (DLS) on a Malvern Zetasizer (Westborough, MA). The ND morphology was assessed by transmission electron microscopy (TEM). Properly diluted ND sample solution was deposited on a carbon film-coated 400 mesh copper grid (Electron Microscopy Sciences) and dried for 1 min. The ND samples were then negatively stained with 1% (w/v) uranyl formate, and the grid was dried before TEM observation. All specimens were imaged on a 100 kV Morgagni TEM equipped with a Gatan Orius CCD.
Cell culture
Bone marrow-derived dendritic cells (BMDCs) were prepared as described previously [35] . Briefly, femur and tibia were harvested aseptically from C57BL/6 mice, and the bone marrow was flushed into a petri dish using a 5 mL syringe (26 G needle) loaded with BMDC culture media (RPMI 1640 supplemented with 10% FBS, 100 U/mL penicillin, 100 μg/mL streptomycin, 50 μM β-mercaptoethanol, and 20 ng/mL GM-CSF). Cells were collected by passing the cell suspension through a cell strainer (mesh size = 40 μm), followed by centrifugation. Cells were seeded into non-tissue culture treated petri-dish at a density of 2 × 10 5 cells/mL, cultured at 37°C with 5% CO 2 . Culture media were refreshed on days 3, 6, 8, and 10, and BMDCs were used for the following assays on days 8-12. B16F10-OVA cells were kindly provided by Dr. Darrell Irvine at Massachusetts Institute of Technology MIT (Cambridge, MA). TC-1 cells were kindly provided by Dr. T. C. Wu at Johns Hopkins University (Baltimore, MD). The TC-1 tumor model was generated by transformation of primary lung epithelial cells from C57BL/6 mice with active Ras together with HPV-16 E6 and E7 oncogenes [36] . Both cell lines were maintained in RPMI1640 medium supplemented with 10% FBS, 100 U/mL penicillin and 100 μg/mL streptomycin. HEK cells transfected with TLR2, TLR4, or TLR9 (InvivoGen, San Diego, CA) were incubated with nanodiscs containing 0.5 μg/mL CpG and/or 0.05 μg/mL MPLA for 24 h, and activation of TLR signaling pathways was detected by following the manufacturer's instructions.
BMDC activation
Immature BMDCs were plated at 1 × 10 6 cells/well in 12-well plates. After 24 h, BMDCs were washed once with PBS and incubated with formulations containing 0.5 μg/mL CpG and/or 0.05 μg/mL MPLA for 24 h at 37°C with 5% CO 2 . After 24 h of incubation, the levels of IL12p70 in the supernatant were measured by the ELISA kit (R&D systems) following the manufacturer's instructions. Uptake of NDs by BMDCs was measured after incubating BMDCs with nanodiscs containing 0.3% mol of DiD. To measure the levels of co-stimulatory markers, BMDCs incubated with ND samples were harvested, washed with FACS buffer (1% BSA in PBS), incubated with anti-CD16/32 at room temperature for at least 10 min, and then stained with fluorophore-labeled antibodies against CD80, and CD86 at room temperature for 30 min. Finally, the cells were washed twice with FACS buffer, resuspended in 2 μg/mL DAPI solution, and analyzed by flow cytometry (Cyan 5, Beckman Coulter, USA).
In vivo immunization study
Animals were cared for following federal, state, and local guidelines. All work performed on animals was in accordance with and approved by University Committee on Use and Care of Animals (UCUCA) at the University of Michigan, Ann Arbor. For the OVA vaccination study, female C57BL/6 mice of age 6-8 weeks (Envigo) were vaccinated 3 times in a 2-week interval by subcutaneous injection in the tail base, each with 10 μg OVA protein dose admixed with indicated adjuvants. For the PCSK9 vaccination study, female Balb/c mice of age 6-8 weeks (Envigo) were vaccinated 3 times in an 1-week interval by subcutaneous injection in the tail base with 0.5-4 μg/dose (0.5 μg/dose for primary vaccination and 4 μg/dose for the two booster vaccinations) of recombinant human PCSK9 (hPCSK9) admixed with indicated adjuvants containing 10 μg/dose CpG and 1 μg/dose MPLA. Serum cholesterol levels at indicated time points were measured using the commercially available Wako Cholesterol E kit (Wako Chemicals, Richmond, VA).
Therapeutic study in tumor-bearing mice
For the therapeutic vaccination studies in B16F10-OVA tumorbearing animals, C57BL/6 mice were inoculated subcutaneously with 2 × 10 5 B16F10-OVA cells on day 0 and vaccinated on days 7, and 13 with indicated formulations containing 10 μg/dose of OVA protein, 10 μg/dose of CpG and/or 1 μg/dose of MPLA. For the therapeutic tumor vaccination studies in TC-1 tumor-bearing animals, C57BL/6 mice were inoculated subcutaneously with 2 × 10 5 TC-1 cells on day 0
and vaccinated by subcutaneous injection in the tail base on days 8 and 14 with the indicated formulations containing 10 μg/dose of E7 peptide, 10 μg/dose of CpG, and 1 μg/dose of MPLA. Tumor growth was monitored every other day, and the tumor volume was calculated using the following equation [37] : tumor volume = length × width 2 × 0.52.
Animals were euthanized when the tumor masses reached 1.5 cm in diameter or when animals became moribund with severe weight loss or ulceration.
Cellular responses induced by ND-MPLA/CpG
Immunized mice were analyzed for the percentages of antigenspecific CD8α + T cells among peripheral blood mononuclear cells (PBMCs) using the tetramer staining assay, as we described previously [38] . In brief, 100 μL of blood was drawn from each mouse on indicated time points by submandibular bleeding, and red blood cells were lysed with ACK lysis buffer. PBMCs were then washed with FACS buffer and blocked by anti-CD16/32 antibody and incubated with peptide-MHC tetramer (e.g. H-2K b -restricted SIINFEKL or H-2D b -restricted RAHYNI-VTF) for 30 min at room temperature. Samples were then incubated with anti-CD8α-APC for 20 min on ice. Cells were washed twice with FACS buffer and resuspended in 2 μg/mL DAPI or 0.5 μg/mL 7AAD solution for analysis by flow cytometry (Cyan 5, Beckman Coulter, USA).
Humoral responses
ELISA plates were coated with OVA in PBS (1 μg/mL) or mPCSK9 in PBS (0.2 μg/mL) with 100 μL/well and incubated overnight at 4°C. Plates were blocked with 1% BSA in PBS for 2 h, and 100 μL of serum in 4-fold serial dilutions was added to 96-well and incubated for 1 h at room temperature. After washing, wells were incubated with rabbit anti-mouse IgG-HRP (1:10000 dilution) for 1 h at room temperature, followed by addition of the HRP substrate, TMB. The enzymatic reaction was stopped by adding 2 N H 2 SO 4 , and the absorbance at 450 nm (OD450) was measured using a microplate reader. The highest dilution with twice the absorbance of background was considered as the endpoint dilution titer [39] .
Statistical analysis
All animal studies were performed after randomization. Data were analyzed by one-or two-way analysis of variance (ANOVA), followed by Tukey's multiple comparisons post-test, or log-rank (Mantel-Cox) test with Prism 6.0 (GraphPad Software). P values < 0.05 were considered statistically significant. All values are reported as means ± SEM with the indicated sample size. No samples were excluded from analysis.
Results and discussion
Preparation and characterization of adjuvant-loaded nanodiscs
Nanodiscs (ND) containing MPLA and/or CpG were prepared by the lyophilization method (Fig. 1a) [29, 31, 32] . Briefly, MPLA was added together with DMPC and 22A in acetic acid, followed by lyophilization and hydration in PBS to form ND containing MPLA (ND-MPLA). As measured by HPLC equipped with ELSD, MPLA was efficiently loaded onto ND with over 80% incorporation efficiency, likely due to the lipidlike properties of MPLA [40] . As visualized by TEM, ND samples were homogeneous with the average diameter of 10 nm (Fig. 1b) . To co-load MPLA and CpG into ND samples, pre-formed ND-MPLA was incubated with cholesterol modified CpG for 30 min at room temperature (Fig. 1a) . The incorporation efficiency of CpG as determined by GPC was over 95%, as long as the amount of CpG added was < 200 μg/mL per 2 mg/mL (lipid amount) of ND (Fig. 1c) . When > 400 μg/mL of CpG was added, a significant amount of CpG remained unincorporated (Fig. 1c) . Based on this, we chose to use no > 200 μg/mL of CpG to prepare CpG-loaded ND samples. We also examined the hydrodynamic size of ND-MPLA/CpG with DLS immediately after synthesis versus after an extended storage. ND-MPLA/CpG samples that were lyophilized, stored for 2 months at −20°C, and reconstituted in endotoxinfree water exhibited an essentially equivalent hydrodynamic size of 10.1 ± 0.8 nm as freshly prepared ND-MPLA/CpG samples (Fig. 1d) , indicating their suitability for long-term storage. Overall, these results indicate that adjuvant-loaded nanodiscs are homogenous and ultrasmall in size, which may contribute to efficient lymph node draining as we have shown previously [33] . In addition, these dual adjuvant nanodiscs can be readily stored in a lyophilized form for an extended period of time without affecting their size and homogeneity, which may facilitate the transport, storage, and clinical use of adjuvant-loaded nanodiscs.
Potent DC activation by adjuvant-loaded nanodiscs
One of the major effects of adjuvants is to induce costimulatory R. Kuai et al.
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signals on antigen-presenting cells and promote secretion of pro-inflammatory cytokines, which are required for potent elicitation of adaptive immune responses. Using HEK-TLR4 and HEK-TLR9 cell lines, we confirmed that the extent of TLR4 or TLR9 activation was similar between ND-MPLA/CpG and respective treatment with either ND-MPLA or ND-CpG (Fig. 2a) , whereas TLR2 activation was minimal. These results indicated that the dual ND-MPLA/CpG adjuvant system maintained the TLR4 and TLR9 activating-capacity of MPLA and CpG.
To examine the impact of ND-mediated adjuvant delivery on APCs, we incubated BMDCs in vitro with various adjuvant formulations and evaluated costimulatory signals and cytokine release. The extent of BMDC uptake for blank ND, ND-MPLA, NP-CpG, and ND-MPLA/CpG was similar (Fig. 2b ). BMDCs incubated with blank ND without any adjuvants did not upregulate co-stimulatory markers, CD80 or CD86 (Fig. 2c,d ). Compared with soluble MPLA, delivery of MPLA via ND (ND-MPLA) resulted in 2-fold and 3.7-fold increases in the expression levels of CD80 and CD86, respectively (P < 0.0001, Fig. 2c-f ). Compared with soluble CpG, delivery of CpG via ND (ND-CpG) resulted in 1.2-fold increase in the expression level of CD80 (P < 0.05, Fig. 2c,d ).
Co-delivery of MPLA and CpG in ND (ND-MPLA/CpG) led to significantly improved up-regulation of CD80 and 86, with 2.1-fold and 1.6-fold respective enhancements, compared with free admixture of MPLA and CpG (P < 0.0001, Fig. 2c-f) . Notably, ND-MPLA/CpG improved CD80 activation by 1.3-fold and 3-fold, compared with ND-MPLA and ND-CpG, respectively (P < 0.0001, Fig. 2c,d) . Similarly, the expression levels of CD86 were increased 1.4-fold and 5.8-fold with ND-MPLA/CpG, compared with ND-MPLA and ND-CpG, respectively (P < 0.0001, Fig. 2e,f) . We also observed robust secretion of IL-12p70 from BMDCs treated with ND-MPLA/CpG (P < 0.0001, Fig. 2g ), whereas other adjuvant formulations produced low or non-detectable levels of IL-12p70. Taken all together, these results indicate that ND serves as a non-immunogenic, "blank" platform upon which adjuvant(s) can be efficiently incorporated. We have also demonstrated that ND coloaded with MPLA and CpG is more effective at activating DCs in vitro, compared with free adjuvants or even ND containing a single adjuvant.
Humoral immune responses elicited by adjuvant-loaded nanodiscs
Having shown immune activation in vitro (Fig. 2) , we next sought to determine the optimal dose of ND for immunogenicity studies in vivo. Naïve C57BL/6 mice were vaccinated three times in a 2-week interval with various doses of ND-MPLA/CpG admixed with a fixed dose of 10 μg OVA protein employed as a model antigen. On day 7 after the third vaccination, we examined anti-OVA IgG titers in animal sera. The ND dose containing 1 μg MPLA and 10 μg CpG (shown as "1×" dose) was required to induce statistically significant anti-OVA IgG responses (P < 0.05, compared with the non-treated control, Fig. 3a) . While increasing the dose of adjuvants to 2 μg MPLA and 20 μg CpG (shown as "2×" dose) improved anti-OVA IgG titers, this increase was not significantly different from the "1×" dose of OVA+ND-MPLA/CpG (Fig. 3a) , perhaps due to "saturation" of the humoral immune responses at the "1×" dose. Hence, we performed the next studies using the "1×" dose of adjuvants and directly compared ND versus soluble formulations (Fig. 3b) . C57BL/6 mice immunized three times with OVA+ND-MPLA/CpG ("1×" dose in each vaccine) generated strong antibody responses, achieving 13-fold and 4-fold higher anti-OVA IgG titers than OVA+ND-MPLA (P < 0.05) and OVA+ND-CpG (not statistically significant), respectively (Fig. 3b) . A similar trend was observed when the adjuvants were administered in a free form; admixture of OVA with free MPLA and CpG (OVA+MPLA/CpG, "1×" dose) generated 13-fold and 3-fold higher anti-OVA IgG titers than OVA+MPLA (P < 0.05) and OVA+CpG (not statistically significant), respectively (Fig. 3b) . We did not observe any statistically significant differences between anti-OVA IgG titers induced by OVA+ND-MPLA/CpG or the soluble formulation (Fig. 3b) . This might be because the mixture of MPLA/CpG is already a potent adjuvant system that can achieve "saturated" humoral immune responses [20] .
To validate these results in a second mouse strain with an antigen other than OVA, we performed immunization studies in Balb/c mice using ND-MPLA/CpG admixed with recombinant human PCSK9 protein. PCSK9 is known to bind to LDL receptors (LDLR) and promote degradation of LDLR responsible for recycling of cholesterol, thus inducing higher cholesterol levels [41] . Hence, blocking circulating PCSK9 with anti-PCSK9 antibodies or other therapeutics may reduce cholesterol levels, as reported in recent studies [39, 42, 43] . In our studies, Balb/c mice vaccinated on weeks 0, 1, and 2 with PCSK9 + ND-MPLA/CpG generated similar levels of anti-mouse PCSK9 IgG responses as the free dual adjuvants (Fig. 3c) , analogous to the case with OVA protein (Fig. 3b ) Interestingly, compared with the non-treated control group, animals vaccinated with ND-MPLA/CpG exhibited 17-30% reduction in their total cholesterol levels for at least 7 weeks (P < 0.001, Fig. 3d) ; however, by week 11, the total cholesterol levels returned to the normal levels (P > 0.05, Fig. 3d ). On the other hand, the soluble MPLA/CpG formulation induced more transient reduction in the total cholesterol levels, which returned to the normal levels by week 7 (P > 0.05, Fig. 3d ). These transient effects of anti-PCSK9 vaccines have been reported previously [42] , and potentially could be overcome by reactivation of anti-PCSK9 IgG responses with boost immunizations for long-term cholesterol management [42] . 
Robust CD8+ T cell responses elicited by dual adjuvant-loaded nanodiscs
We next examined CD8+ cytotoxic T lymphocyte (CTL) responses generated by adjuvant-loaded ND. First, we determined the dose-dependence of CTL responses on ND-MPLA/CpG vaccination. Naïve C57BL/6 mice were vaccinated three times in a 2-week interval with various doses of ND-MPLA/CpG admixed with a fixed dose of 10 μg OVA protein. On day 7 after the third vaccination, we quantified the frequency of OVA-specific CD8+ T cells among peripheral blood mononuclear cells (PBMCs) by the tetramer staining assay. Vaccination with the ND dose of 1 μg MPLA and 10 μg CpG (shown as "1×" dose) elicited the highest level of SIINFEKL-tetramer+ CD8+ T cell responses at 5.5 ± 1.7% (Fig. 4a) . When the dose of adjuvant was lower than 10 μg/dose CpG and 1 μg/dose MPLA, the CD8+ T cell responses were not statistically different from the non-treated control group. On the other hand, when the dose was higher than 10 μg/dose CpG and 1 μg/dose MPLA, the T cell responses started to decrease (Fig. 4a) , potentially due to overt immune activation [44] . Having shown the ND co-loaded with 1 μg MPLA and 10 μg CpG as the ideal dose for T cell responses, we investigated the impact of adjuvant delivery via either ND or soluble forms on elicitation of antigen-specific CD8+ T cell responses. Three immunizations with OVA+ND-MPLA/CpG ("1×" dose) generated robust antigen-specific CD8+ T cell responses among PBMCs, achieving 3.3-fold higher frequency of SIINFEKL-tetramer+ CD8+ T cells than the equivalent dose of soluble OVA+MPLA+CpG vaccine (P < 0.05, Fig. 4b,c) . OVA+ND-MPLA/CpG vaccination also enhanced antigen-specific CD8+ T cell responses, compared with OVA+ND-MPLA (a 7-fold increase, P < 0.001) and OVA+ND-CpG (a 1.6-fold increase, although this was not statistically significant) (Fig. 4b,c) .
Therapeutic efficacy of vaccine nanodiscs against B16F10-OVA melanoma
Having shown that ND-MPLA/CpG induces potent cellular and humoral immune responses, we next sought to examine their efficacy as a therapeutic vaccine in tumor-bearing animals (Fig. 5a ). C57BL/6 mice were inoculated with B16F10-OVA melanoma cells in the s.c. flank. On day 7 when the tumors were established with the average volume of 70 mm 3 , the animals were administered s.c. at tail base with 10 μg/dose of OVA protein admixed with 1 μg/dose of MPLA and/or 10 μg/dose of CpG in either soluble or ND formulations. On 13, a boost dose was given, and on day 20, the percentages of antigen-specific CD8+ T cells among PBMCs were analyzed by the tetramer staining assay (Fig. 5a ).
Compared with OVA admixed with free adjuvant(s), OVA+ND-MPLA/ CpG significantly enhanced antigen-specific CTL responses with~10% tetramer+ CD8+ T cells, representing 10-fold, 4.9-fold, and 8.1-fold increases than OVA+MPLA (P < 0.0001), OVA+CpG (P < 0.001), and OVA+MPLA/CpG (P < 0.0001), respectively (Fig. 5b,c) . Importantly, OVA+ND-MPLA/CpG also generated 5-fold and 2-fold higher antigen-specific CD8+ T cell responses than OVA+ND-MPLA (P < 0.001) and OVA+ND-CpG (P < 0.05), respectively (Fig. 5b,c) . Moreover, OVA+ND-MPLA/CpG also generated strong anti-OVA IgG responses in these tumor-bearing animals (Fig. 5d) . We also monitored tumor growth in these animals. ND-mediated delivery of MPLA or CpG as a single adjuvant improved the therapeutic efficacy of the vaccines (Fig. 5e,f) ; treatments with OVA+ND-MPLA or OVA+ND-CpG led to stronger suppression of tumor progression, compared with OVA+MPLA (P < 0.0001, Fig. 5e ) or OVA+CpG (P < 0.05, Fig. 5f ). Importantly, treatments with OVA+ND-MPLA/ CpG led to potent regression of established tumors and exerted significantly enhanced anti-tumor efficacy, compared with its soluble OVA+MPLA/CpG control (P < 0.0001, Fig. 5g) . Notably, compared with all the other soluble or ND formulations, ND-MPLA/CpG vaccination generated significantly stronger T cell responses (Fig. 5b-c) and mediated tumor regression (Fig. 5g) , whereas treatments with ND-MPLA, ND-CpG, or soluble MPLA/CpG admixture only resulted in maintenance of tumor size (Fig. 5e-f) . Overall, these results indicate that ND carrying the dual adjuvants elicited strong and balanced cellular and humoral immune responses with potent therapeutic efficacy against established tumors.
Therapeutic efficacy of vaccine nanodiscs against HPV-associated TC-1 carcinoma
Finally, to confirm our results in a second tumor model with a tumor antigen other than OVA, we have evaluated the therapeutic efficacy of our strategy against TC-1 cell line, which contains the E7 oncogene from human papillomavirus (HPV) type 16 [36] -a widely used preclinical model for HPV-associated cancers [45] . C57BL/6 mice were inoculated with TC-1 cells in the right flank (Fig. 6a) . On day 8 when the tumors were established with the average volume of 70 mm 3 , the animals were administered s.c. at tail base with 10 μg/dose of E7 peptide (GQAEPDRAHYNIVTFCCKCD, with RAHYNIVTF as the H2-D b -restricted E7 epitope) admixed with 1 μg/dose of MPLA and/or 10 μg/dose of CpG in either soluble or ND formulations. On 14, a boost dose was given, and on day 20, the percentages of E7-specific CD8+ T cells among PBMCs were measured by the tetramer staining assay (Fig. 6a) . Vaccinations with E7 + ND-MPLA/CpG markedly improved elicitation of E7-specific CD8+ T cells, achieving~20% tetramer+ responses on day 20, which were 222-fold and 2-fold greater than those induced endogenously in non-treated, tumor-bearing mice (P < 0.001) and soluble E7 + MPLA/CpG treated, tumor-bearing mice (P < 0.05), respectively ( Fig. 6b-c) . Furthermore, compared with the soluble control, E7 + ND-MPLA/CpG treatment exerted significantly enhanced anti-tumor efficacy, leading to regression of TC-1 tumors (P < 0.0001, Fig. 6d ) and all animals surviving tumor free throughout the study (Fig. 6e) . Taken all together, nanodiscs co-loaded with the dual adjuvants elicit robust anti-tumor CD8+ T cell responses and inhibit established TC-1 tumors more effectively than the free dual adjuvants.
Conclusions
Here we report the development of homogeneous and ultrasmall nanodiscs that can co-deliver multiple adjuvants (e.g. a TLR4 agonist
